Table 1.
Patient and tumor characteristics and pattern of failure
| Variables | SIB group | SeqB group | Total | p-value |
|---|---|---|---|---|
| Pts N (%) | Pts N (%) | Pts N (%) | ||
| Sex | ||||
| Female | 64 (73.6) | 76 (73.8) | 140 (73.7) | 0.9722 |
| Male | 23 (26.4) | 27 (26.2) | 50 (26.3) | |
| Median age (range) | 64 (55–70) | 62 (53–77) | 63 (53–77) | a0.4471 |
| Subsite | ||||
| Anal canal | 73 (83.9) | 80 (77.7) | 153 (80.5) | <.0001 |
| Anal margin | 14 (16.1) | 23 (22.3) | 37 (19.5) | |
| Histologic type | ||||
| Basaloid | 7 (8.0) | 7 (6.8) | 14 (7.4) | 0.7425 |
| Squamous cell | 80 (92.0) | 96 (93.2) | 176 (92.6) | |
| Grading | ||||
| NA | 2 (2.4) | 19 (18.4) | 21 (11.1) | |
| G1 | 7 (8.0) | 28 (27.2) | 35 (18.4) | 0.0003 |
| G2 | 57 (65.5) | 39 (37.9) | 96 (50.5) | |
| G3 | 21 (24.1) | 17 (16.5) | 38 (20.0) | |
| T stage | ||||
| T1 | 5 (5.8) | 4 (3.9) | 9 (4.7) | 0.0725 |
| T2 | 55 (63.2) | 57 (55.3) | 112 (59.0) | |
| T3 | 23 (26.4) | 25 (24.3) | 48 (25.3) | |
| T4 | 4 (4.6) | 17 (16.5) | 21 (11.0) | |
| N stage | ||||
| N0 | 57 (65.5) | 53 (51.5) | 110 (57.9) | 0.0015 |
| N1 | 5 (5.8) | 17 (16.5) | 22 (11.6) | |
| N2 | 21 (24.1) | 15 (14.6) | 36 (18.9) | |
| N3 | 4 (4.6) | 18 (17.4) | 22 (11.6) | |
| Global stage | ||||
| I | 5 (5.7) | 3 (2.9) | 8 (4.2) | 0.0730 |
| II | 49 (56.3) | 44 (42.7) | 93 (48.9) | |
| IIIA | 8 (9.3) | 21 (20.4) | 29 (15.3) | |
| IIIB | 25 (28.7) | 35 (34.0) | 60 (31.6) | |
| Inguinal node involv. | ||||
| NA | 0 (0%) | 1 (1) | 1 (0.6) | 0.0187 |
| Yes | 18 (20.7) | 37 (35.9) | 55 (28.9) | |
| No | 69 (79.3) | 65 (63.1) | 134 (70.5) | |
| Time biopsy-RT (days) | ||||
| ≥ 60 | 62 (71.3) | 5 (4.9) | 67 (35.3) | 0.0172 |
| < 60 | 25 (28.7) | 98 (95.1) | 123 (64.7) | |
| OTT (days) | ||||
| < 45 | 62 (71.3) | 5 (4.9) | 67 (35.3) | <.0001 |
| ≥ 45 | 25 (28.7) | 98 (95.1) | 123 (64.7) | |
aU-Mann Whitney Test
Legend: SIB simultaneous integrated boost, SeqB sequential boost, pts patients, N: number; involv.: Involvement, RT radiotherapy; OTT overall treatment time